Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.22 USD | +1.90% | +14.00% | -14.00% |
09/05 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
09/05 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.00% | 248.23Cr | |
+29.77% | 4.92TCr | |
+1.00% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.68% | 2.61TCr | |
-22.99% | 1.87TCr | |
+8.22% | 1.33TCr | |
+32.41% | 1.23TCr | |
-1.62% | 1.2TCr |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Citigroup Adjusts Price Target on Intellia Therapeutics to $44 From $39, Maintains Neutral Rating